CDK8 and breast carcinoma: CDK8 activity has been successfully reduced by tools like small-molecule inhibitors (like Senexin A and B) and genetic techniques like shRNA or CRISPR/Cas9, demonstrating its potential as a therapeutic target in breast cancer [155].